RxDoctor Payments Data

Malathi Tadakamalla, MD

Geriatric Medicine · Lees Summit, MONPI 1316989197

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Avanir Pharmaceuticals, Inc. at 40.1% of the total.

$581in general payments, 2019–2025

Across 9 payments — averaging $64.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$233
  • Abbott$141
  • Acadia Pharmaceuticals Inc$117
  • Sunovion Pharmaceuticals Inc.$43
  • Novartis$27
  • Sumitomo Pharma America, Inc.$19

What the payments were for

  • Food & beverage$581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$581 in reported general payments places this provider in the 60th percentile of 76 geriatric medicine providers in Missouri.

See all geriatric medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$156,314
Medicare patients
499
Services billed
1,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban818$217,020
Tolvaptan12$86,566
NuedextaDextromethorphan Hbr/Quinidine69$57,995
XifaxanRifaximin31$46,701
JardianceEmpagliflozin167$45,173
RexultiBrexpiprazole53$34,767
NuplazidPimavanserin Tartrate11$30,154
Invega SustennaPaliperidone Palmitate11$28,333
XareltoRivaroxaban77$24,098
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$21,475
LinzessLinaclotide24$13,742
MyrbetriqMirabegron53$12,780
GemtesaVibegron53$12,632
Potassium Chloride606$11,957
Memantine Hcl238$11,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$233$57,99569 claims
Acadia Pharmaceuticals IncNuplazid$117$30,15411 claims
Sumitomo Pharma America, Inc.Gemtesa$19$12,63253 claims
NovartisEntresto$27$9,42032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 76 geriatric medicine providers in Missouri.

Other geriatric medicine in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →